featured
Eptinezumab Shows Efficacy in Sustained Prevention of Migraine From Day 1
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Headache
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing
Headache 2020 Nov 01;60(10)2220-2231, DW Dodick, C Gottschalk, R Cady, J Hirman, J Smith, S SnapinnFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.